Delisting
With effect from September 6, 2023, Labomar Spa shares have been delisted from trading on Euronext Growth Milan.
AXIS 1 "RESEARCH, TECHNOLOGICAL DEVELOPMENT AND INNOVATION
ACTION 1.1.4 “Support for collaborative R&D activities for the development of new sustainable technologies, products and services”
ACTION 1.1.4 “Support for collaborative R&D activities for the development of new sustainable technologies, products and services”
PRELIMINARY EFFICACY STUDY OF A FOOD SUPPLEMENT TO SUPPORT NCGS (Non-celiac gluten sensitivity) AND COELIAC DISEASE
Design and manufacture of a food supplement containing a plant enzyme and a probiotic. Study of the plant enzyme's proteolytic activity against gluten and the anti-inflammatory activity of the combination of active ingredients. Development of the finished product to improve its stability in terms of the viability of the probiotic strain.
Intervention realised with funding POR FESR 2014-2020 (Objective: '"Increasing business innovation activity").
Intervention carried out with the benefit of a grant from Regione Veneto amounting to euro 79.150.
PRODUCTION AND CHARACTERISATION OF AN AMARANTH EXTRACT FOR CARDIOVASCULAR HEALTH
Investigation and development of a food alternative with a health-promoting effect on the cardiovascular system. Field and vertical cultivations of different varieties of Amaranthus caudatus, production and characterisation of fluid extracts and simultaneous evaluation of biological activity.
Intervention realised with funding POR FESR 2014-2020 (Objective: "Increasing business innovation activity").
Intervention carried out with the benefit of a grant from Regione Veneto amounting to euro 35.375.
Thanks to the Regione Veneto and the European Union, Labomar has obtained important funding for the development of botanical extracts and food supplements to support health.
The precise study of products and the acquisition of new skills will enable Labomar to make important improvements in the production, proposition and positioning of its products.
Our focus is always on improving the entire production chain, services and the continuous raising of our quality standards, so that we can also address the most important international brands.
PROJECT SUMMARY
Design and manufacture of a food supplement containing a plant enzyme and a probiotic. Study of the plant enzyme's proteolytic activity against gluten and the anti-inflammatory activity of the combination of active ingredients. Development of the finished product to improve its stability in terms of the viability of the probiotic strain.
Intervention realised with funding POR FESR 2014-2020 (Objective: '"Increasing business innovation activity").
Intervention carried out with the benefit of a grant from Regione Veneto amounting to euro 79.150.
PRODUCTION AND CHARACTERISATION OF AN AMARANTH EXTRACT FOR CARDIOVASCULAR HEALTH
Investigation and development of a food alternative with a health-promoting effect on the cardiovascular system. Field and vertical cultivations of different varieties of Amaranthus caudatus, production and characterisation of fluid extracts and simultaneous evaluation of biological activity.
Intervention realised with funding POR FESR 2014-2020 (Objective: "Increasing business innovation activity").
Intervention carried out with the benefit of a grant from Regione Veneto amounting to euro 35.375.
Thanks to the Regione Veneto and the European Union, Labomar has obtained important funding for the development of botanical extracts and food supplements to support health.
The precise study of products and the acquisition of new skills will enable Labomar to make important improvements in the production, proposition and positioning of its products.
Our focus is always on improving the entire production chain, services and the continuous raising of our quality standards, so that we can also address the most important international brands.
PROJECT SUMMARY
“Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.